Type I vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation

Prostate

Volumn 42, Issue 2, 2000, Pages 137-144

  Gkonos, Peter J ^a,b,c   Guo, Fang ^a,b   Burnstein, Kerry L ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Androgen receptors; Epithelial cells; Prostate cancer; Vasoactive intestinal peptide receptors

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP; MESSENGER RNA; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; TUMOR MARKER; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL LEVEL; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN DETERMINATION; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CYTOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; IN SITU HYBRIDIZATION; NORTHERN BLOTTING; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; RAT;

ANIMALS; BLOTTING, NORTHERN; CELL DIFFERENTIATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MALE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ANDROGEN; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0033621597     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000201)42:2<137::AID-PROS8>3.0.CO;2-U     Document Type: Article

References (29)

1. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato ACB, Bartsch G, Klocker H. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998;35: 63-70.
2. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostate epithelial cell lines: characteristics and applications. Part 2. Tumorigenic cell lines. Prostate 1997;30: 58-64.
3. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;17:534-540.
4. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK. Androgen-repressed phenotype In human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157.
5. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostate epithelial cell lines: characteristics and applications. Part 1. Cell markers and immortalized nontumorigenic cell lines. Prostate 1996;29:386-394.
6. Plymate SR, Loop SM, Hoop RC, Wiren KM, Ostenson R, Hryb DJ, Rosner W. Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma. J Steroid Biochem Mol Biol 1991; 40:833-839.
7. Said SI. Vasoactive intestinal peptide. J Endocrinol Invest 1986; 9:121-200.
8. Smitherman TC, Dehmer GJ, Said SI. Vasoactive intestinal peptide as a coronary vasodilator. Ann NY Acad Sci 1988;527:421-431.
9. Carmena M-J, Prieto JC. Cyclic AMP response to vasoactive intestinal peptide and β-adrenergic or cholinergic agonists in isolated epithelial cells of rat ventral prostate. Biosci Rep 1985; 5:791-797.
10. Gkonos PJ, Lokeshwar BL, Balkan W, Roos BA. Neuroendocrine peptides stimulate adenyl cyclase in normal and malignant prostate cells. Regul Pept 1995;59:43-51.
11. Sreedharan SP, Huang J-X, Cheung M-C, Goetzl E. Structure, expression, and chromosomal localization of the type 1 human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 1995;92:2939-2943.
12. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995;36:1846-1853.
13. Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids 1996;61:531-539.
14. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811-819.
15. Gkonos PJ, Tavianini MA, Liu CC, Roos BA. Thyrotropin-releasing hormone gene expression in normal thyroid parafollicular cells. Mol Endocrinol 1989;3:2101-2109.
16. 35S- and digoxigenin-labeled probes for in situ hybridization. Expression of mRNA of the seminal vesicle secretion protein II and androgen receptor genes in the rat prostate. Histochemistry 1992;98:217-228.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
18. Sreedharan SP, Patel DR, Huang J-X, Goetzl EJ. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 1993;193:546-553.
19. Gkonos PJ, Ashby M, Andrade A. Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP cells. Regul Pept 1996;65:153-157.
20. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994;135:2662-2680.
21. Ichikawa S, Sreedharan SP, Owen RL, Goetzl EJ. Immunochemical localization of type 1 VIP receptor and NK-1-type substance P receptor in rat lung. Am J Physiol 1995;268:584-588.
22. Nathanson I, Widdicombe JH, Barnes PJ. Effect of vasoactive intestinal peptide on ion transport across dog tracheal epithelium. J Appl Physiol 1983;55:1844-1848.
23. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-19907.
24. Zhu X, Liu J-P. Steroid-independent activation of androgen receptor in androgen-independent prostate cancer. A possible role for the MAP kinase signal transduction pathway? Mol Cell Endocrinol 1997;134:9-14.
25. Hoosein NM, Logothetis CJ, Chung LKW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide, and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
26. Maruno K, Said SI. Small-cell lung carcinoma: Inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody. Life Sci 1993;52:267-271.
27. Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I, Moody TW. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res 1996;56:3486-3489.
28. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davison A, Gozes I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA 1993;90:4345-4349.
29. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-1121.